Fig. 6: The combination of isoacteoside and sorafenib significantly increased the therapeutic efficacy of HCC. | Communications Biology

Fig. 6: The combination of isoacteoside and sorafenib significantly increased the therapeutic efficacy of HCC.

From: Isoacteoside alleviates hepatocellular carcinoma progression by inhibiting PDHB-mediated reprogramming of glucose metabolism

Fig. 6

A, C CCK8 analysis was used to detect the effects of HY-N0022, sorafenib monotherapy and combination treatment on HCC cell proliferation. B, D Flow cytometry was used to detect the effects of HY-N0022, sorafenib monotherapy and combination treatment on apoptosis of HCC cells. E, F The effects of HY-N0022, sorafenib monotherapy and combination treatment on tumor growth in vivo. Data are presented as means ± standard deviation from three independent experiments; *P < 0.05, **P < 0.01, ***P < 0.001.

Back to article page